World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
22114
World Ranking
16243
National Ranking
8166

Robert J. Kreitman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert J. Kreitman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 347 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert J. Kreitman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert J. Kreitman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert J. Kreitman is affiliated with the National Cancer Institute in the United States. Their research contributions span multiple areas within medicine, with a significant focus on hematologic malignancies and immunological disorders. Kreitman has authored and co-authored numerous scientific papers contributing to the understanding and treatment of various blood cancers and immune system dysfunctions.

Their published work covers key fields of study including Medicine and Immunology and Microbiology. Specific subfields frequently addressed in their research include Genetics, Immunology, Pathology and Forensic Medicine, Molecular Biology, and Oncology.

Main topics explored in their work are:

  • Chronic Lymphocytic Leukemia Research
  • Immunodeficiency and Autoimmune Disorders
  • Lymphoma Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Toxin Mechanisms and Immunotoxins
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research

Some of Kreitman's recent papers include:

  • "Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial," 2021, Journal of Hematology & Oncology
  • "Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia," 2020, Journal of Clinical Oncology
  • "Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries," 2022, Nature Genetics
  • "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study," 2022, Annals of Oncology
  • "Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial," 2023, Nature Medicine

Kreitman collaborates frequently with several notable co-authors. The most frequent collaborators are:

  • Evgeny Arons (26 collaborations)
  • Hong Zhou (13 collaborations)
  • Hao-Wei Wang (12 collaborations)
  • Constance M. Yuan (11 collaborations)
  • Mark Raffeld (10 collaborations)

The most common venues for Kreitman's publications include:

  • Blood (13 publications)
  • Leukemia (4 publications)
  • Leukemia & lymphoma / Leukemia and lymphoma (4 publications)
  • Journal of Clinical Oncology (3 publications)
  • Blood Advances (2 publications)

Best Publications

  • Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

    Vivek Subbiah;Robert J. Kreitman;Zev A. Wainberg;Jae Yong Cho

  • Immunotoxin Therapy of Cancer

    Ira Pastan;Raffit Hassan;David J. FitzGerald;Robert J. Kreitman

  • Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

    Robert J. Kreitman;Wyndham H. Wilson;Karen Bergeron;Miranda Raggio

  • Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

    Robert J. Kreitman;Wyndham H. Wilson;Jeffrey D. White;Maryalice Stetler-Stevenson

  • Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

    Raffit Hassan;Susie Bullock;Ahalya Premkumar;Robert J. Kreitman

  • Immunotoxin Treatment of Cancer

    Ira Pastan;Raffit Hassan;David J. FitzGerald;Robert J. Kreitman

  • Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Martin S. Tallman;Tadeusz Robak;Steven Coutre

  • Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

    Robert J. Kreitman;David R. Squires;Maryalice Stetler-Stevenson;Pierre Noel

  • Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

    Robert W. Rand;Robert J. Kreitman;Nicholas Patronas;Frederick Varricchio

  • Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

    Robert J. Kreitman;Ira Pastan

  • Immunotoxins in cancer therapy.

    Robert J Kreitman

  • Ablation of Cerebellar Golgi Cells Disrupts Synaptic Integration Involving GABA Inhibition and NMDA Receptor Activation in Motor Coordination

    Dai Watanabe;Hitoshi Inokawa;Kouichi Hashimoto;Norimitsu Suzuki

  • Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

    Robert J. Kreitman;Raffit Hassan;David J. FitzGerald;Ira Pastan

  • High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias

    Joshua J Waterfall;Evgeny Arons;Robert L Walker;Marbin Pineda

  • Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Maryalice Stetler-Stevenson;Inger Margulies;Pierre Noel

  • Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

    Michael R. Grever;Omar Abdel-Wahab;Leslie A. Andritsos;Versha Banerji

  • Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions

    Yoram Reiter;Ulrich Brinkmann;Robert J. Kreitman;Sun-Hee Jung

  • Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

    Raffit Hassan;Andrew C. Miller;Elad Sharon;Anish Thomas

  • Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

    Robert J. Kreitman;Claire Dearden;Pier Luigi Zinzani;Julio Delgado

  • Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

    Liqiang Xi;Evgeny Arons;Winnifred Navarro;Katherine R. Calvo

Frequent Co-Authors

Ira Pastan
Ira Pastan Center for Cancer Research
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
David J. FitzGerald
David J. FitzGerald MRC Laboratory of Molecular Biology
Wyndham H. Wilson
Wyndham H. Wilson National Institutes of Health
Raj K. Puri
Raj K. Puri US Food and Drug Administration
Mark Raffeld
Mark Raffeld National Institutes of Health
Tadeusz Robak
Tadeusz Robak Medical University of Lodz
Mark C. Willingham
Mark C. Willingham Wake Forest University
Byungkook Lee
Byungkook Lee National Institutes of Health
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medicine but seeking alternate pathways or additional qualifications, a range of online options are available. For those looking to start their careers quickly, fast track lpn programs provide a streamlined route into nursing, with flexible online coursework designed to help you enter the workforce faster.

For registered nurses aiming to specialize further, accelerated msn psychiatric np programs offer a rapid way to gain advanced mental health skills. These focused online programs are ideal for those passionate about psychiatric nursing and patient care.

Students interested in managing healthcare facilities or advancing into administration roles should consider a healthcare administration degree. Comparing healthcare administration degree cost is essential to make informed choices and minimize student debt.

For those pursuing graduate studies, finding the cheapest mha online programs can make a master’s degree more accessible and affordable. These programs can open doors to high-level leadership roles within the healthcare sector.

Best Scientists Citing Robert J. Kreitman

Trending Scientists

Recently Published Articles